ArticlePloS one2026
Lipidomic analysis of bile from patients with extrahepatic cholangiocarcinoma.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCholangiocarcinoma and gallstones are significant gastrointestinal diseases with diverse etiologies and complex clinical manifestations. Understanding their underlying molecular mechanisms is crucial for advancing diagnosis and treatment strategies. In this study, we compared the lipidomic profiles of bile samples from patients with extrahepatic cholangiocarcinoma (eCCA) or choledocholithiasis with those of healthy controls to identify potential biomarkers and therapeutic targets.
methodsBile samples were prospectively collected from 33 patients undergoing endoscopic retrograde cholangiopancreatography at the Korea University Guro Hospital, including 12 patients with eCCA, 15 with choledocholithiasis, and six controls. Lipidomic profiling was performed using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry. Principal component analysis, ANOVA, and volcano plots were used to identify the differential lipidomic signatures across the groups.
resultsA total of 230 lipid metabolites were identified, and significant differences were observed among the groups; each group had distinct lipidomic patterns. In both eCCA and choledocholithiasis, phosphatidylcholine contents were consistently more downregulated than in controls. However, diacylglycerol lipids were upregulated in eCCA while acylcarnitine lipids were upregulated in choledocholithiasis. Lysophosphatidylcholine levels were notably lower in patients with eCCA than in those with choledocholithiasis.
conclusionOur results suggested that specific lipidomic changes and their inter-relationships contribute to the pathophysiology of choledocholithiasis and eCCA. Longitudinal studies and functional assays can further validate the findings and translate them into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.